Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.

Research output: Contribution to journalArticle

Abstract

Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) -associated breast and ovarian cancers. We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-associated cancers.

Details

Authors
  • Bella Kaufman
  • Ronnie Shapira-Frommer
  • Rita K Schmutzler
  • M William Audeh
  • Michael Friedlander
  • Judith Balmaña
  • Gillian Mitchell
  • Georgeta Fried
  • Salomon M Stemmer
  • Ayala Hubert
  • Ora Rosengarten
  • Mariana Steiner
  • Niklas Loman
  • Karin Bowen
  • Anitra Fielding
  • Susan M Domchek
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)244-U134
JournalJournal of Clinical Oncology
Volume33
Issue number3
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes